178 related articles for article (PubMed ID: 32259323)
1. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
Msaouel P; Malouf GG; Su X; Yao H; Tripathi DN; Soeung M; Gao J; Rao P; Coarfa C; Creighton CJ; Bertocchio JP; Kunnimalaiyaan S; Multani AS; Blando J; He R; Shapiro DD; Perelli L; Srinivasan S; Carbone F; Pilié PG; Karki M; Seervai RNH; Vokshi BH; Lopez-Terrada D; Cheng EH; Tang X; Lu W; Wistuba II; Thompson TC; Davidson I; Giuliani V; Schlacher K; Carugo A; Heffernan TP; Sharma P; Karam JA; Wood CG; Walker CL; Genovese G; Tannir NM
Cancer Cell; 2020 May; 37(5):720-734.e13. PubMed ID: 32359397
[TBL] [Abstract][Full Text] [Related]
3. Renal medullary carcinomas depend upon
Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
Elife; 2019 Mar; 8():. PubMed ID: 30860482
[TBL] [Abstract][Full Text] [Related]
4. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
6. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
7. Renal medullary carcinoma in a young mixed-race man in Japan.
Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
[TBL] [Abstract][Full Text] [Related]
8. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
Msaouel P; Tannir NM; Walker CL
Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
[TBL] [Abstract][Full Text] [Related]
9. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Renal Medullary Carcinoma.
Su Y; Hong AL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
[TBL] [Abstract][Full Text] [Related]
11. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
[TBL] [Abstract][Full Text] [Related]
12. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
Calderaro J; Masliah-Planchon J; Richer W; Maillot L; Maille P; Mansuy L; Bastien C; de la Taille A; Boussion H; Charpy C; Jourdain A; Bléchet C; Pierron G; Gentien D; Choudat L; Tournigand C; Delattre O; Allory Y; Bourdeaut F
Eur Urol; 2016 Jun; 69(6):1055-61. PubMed ID: 26433572
[TBL] [Abstract][Full Text] [Related]
13. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
[TBL] [Abstract][Full Text] [Related]
14. A case of renal cell carcinoma unclassified with medullary phenotype without detectable gene deletion.
Tsuzuki S; Kataoka TR; Ito H; Ueshima C; Asai S; Yokoo H; Haga H
Pathol Int; 2019 Dec; 69(12):710-714. PubMed ID: 31617267
[TBL] [Abstract][Full Text] [Related]
15. SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M; Perelli L; Chen Z; Dondossola E; Ho IL; Carbone F; Zhang L; Khan H; Le CN; Zhu C; Peoples MD; Feng N; Jiang S; Zacharias NM; Minelli R; Shapiro DD; Deem AK; Gao S; Cheng EH; Lucchetti D; Walker CL; Carugo A; Giuliani V; Heffernan TP; Viale A; Tannir NM; Draetta GF; Msaouel P; Genovese G
Proc Natl Acad Sci U S A; 2023 May; 120(21):e2209639120. PubMed ID: 37186844
[TBL] [Abstract][Full Text] [Related]
16. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas.
Tan KT; Kim H; Carrot-Zhang J; Zhang Y; Kim WJ; Kugener G; Wala JA; Howard TP; Chi YY; Beroukhim R; Li H; Ha G; Alper SL; Perlman EJ; Mullen EA; Hahn WC; Meyerson M; Hong AL
Genome Med; 2021 Jul; 13(1):114. PubMed ID: 34261517
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
[TBL] [Abstract][Full Text] [Related]
18. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
19. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
20. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
